Pancreatic Cancer Research

ResearcherUniversity of BonnNo recent work listed

Martin Schlesinger

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8942-6136; OpenAlex author ID A5022422907. Sources: OpenAlex.

Their work

Papers
2 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
4
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper

Papers 2

  1. A Combined Activity of Thrombin and P-Selectin Is Essential for Platelet Activation by Pancreatic Cancer Cells. Last author DOI 10.3390/ijms22073323↗
  2. A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies. First author DOI 10.1186/s12951-016-0209-6↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Reza Haschemi · 1 shared paper, 2021 · strength 0.19
  2. Georg Feldmann · 1 shared paper, 2016 · strength 0.06
  3. Savita Bisht · 1 shared paper, 2016 · strength 0.06
  4. Stefan Holdenrieder · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.